{
  "docId": "019dd923-5e88-73ef-bd5b-14c31e0c6f76",
  "docSlug": "71f6bd7b1ee963b8",
  "documentTitle": "250115 ucb company presentation jpm",
  "authorId": "JPMorgan",
  "authorName": "UCB",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "equity_research",
  "sourceTypeLabel": "Equity research",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 6,
  "pageCount": 13,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses a dual-column layout to contrast current commercial success with future pipeline growth.",
  "elementsJson": [
    "headline_text",
    "icon_grid",
    "big_number",
    "other"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5e88-73ef-bd5b-14c31e0c6f76/6",
  "deckHref": "/decks/019dd923-5e88-73ef-bd5b-14c31e0c6f76",
  "deckJsonHref": "/decks/019dd923-5e88-73ef-bd5b-14c31e0c6f76.json",
  "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5b-14c31e0c6f76#slide-6",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "We have in our hands a STRONG COMMERCIAL PORTFOLIO and CUTTING-EDGE PIPELINE",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-28a9-71be-8070-a0051ea1ebc4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.19,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "IL = interleukin; DS = Dravet Syndrome; LGS = Lennox-Gastaut Syndrome; AChR+ = Acetylcholinesterase Receptor Positive; gMG = generalized Myasthenia Gravis; MUSK+ = Muscle Specific Kinase Positive; * Comprehensive update to be shared in FEB25 with UCB Full-year Results",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18e3a650-f2ca-4b54-acca-6beb1b740b24",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.55,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "list",
      "text": "Bimzelx: First and only IL-17A & IL-17F inhibitor; EVENITY: Only sclerostin-inhibitor; Fintepla: Foundational therapy in DS a recognized option in LGS; RYSTIGGO: First agent for anti-AChR+ & anti-MusK+ gMG; ZILBRYSQ: First and only once-daily subcutaneous C5 inhibitor",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35213982-a193-409d-82c4-b81c295b58d1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.08,
        "x": 0.77,
        "y": 0.35
      },
      "kind": "metric",
      "text": "4 Phase 3 Clinical Development Projects",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "595591b8-d8d3-4bdb-a087-d34e601ab0ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.08,
        "x": 0.89,
        "y": 0.35
      },
      "kind": "metric",
      "text": "1 Submission-ready end of 2024",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c85d5f3-e376-4310-ad3c-66eadd9577ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.08,
        "x": 0.65,
        "y": 0.35
      },
      "kind": "metric",
      "text": "5 Phase 2 Clinical Development Projects",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "adc93ff4-7be8-42a1-8884-0dda0ef8aed3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.7,
        "x": 0.03,
        "y": 0.1
      },
      "kind": "title",
      "text": "We have in our hands a STRONG COMMERCIAL PORTFOLIO and CUTTING-EDGE PIPELINE",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ccac188-a3a2-4acd-bff3-2e5acc56a6c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Our Present Positions Us",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "07ae3263-e636-4164-81e8-0c85d3773bb8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "760d5db3-09c0-44f8-b0ac-0af248e2b944",
      "evidence": "This slide presents a summary of the company's portfolio and pipeline, highlighting its strengths.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 6,
      "from": 6,
      "beatId": "797df303-6323-437d-a2b3-47d1f8e1d07d",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "Highlighting their strong commercial portfolio and cutting-edge pipeline satisfies the need",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}